# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
NRX Pharmaceuticals (NASDAQ:NRXP) reported quarterly losses of $(0.74) per share which missed the analyst consensus estimate of...
NRX Pharmaceuticals announces Phase 2b/3 trial findings of NRX-101 vs. Lurasidone for Suicidal Bipolar Depression.